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ABSTRACT 
Nasotracheal suctioning (NTS) is a procedure commonly performed by respiratory 
physiotherapists and nurses to remove excess respiratory secretions from the 
tracheobronchial tree in a self-ventilating, non-intubated and non-tracheotomized 
patient. NTS is an important treatment modality for patients with acute secretion 
retention who are at high risk of progressive respiratory deterioration and arrest. 
However, NTS is a blind invasive procedure with risk of serious adverse events, and 
the patient experience of NTS is often extremely negative.  
Capsaicin, a substance extracted from cayenne pepper, elicits reflex coughs when 
inhaled. It is hypothesized that capsaicin-induced reflex cough may offer an 
alternative treatment option to NTS. It is suggested that repeated reflex cough bouts, 
elicited through inhalation of nebulized capsaicin via a facemask, could achieve 
clearance of retained secretions from the tracheobronchial tree to the oropharynx, 
thereby avoiding the need for NTS.  
This hypothesis is supported by preliminary cough flow data from a stroke trial. 
Stroke patients underwent assessments of peak cough flow (PCF, a measure of 
cough effectiveness) of both maximal volitional cough and capsaicin-induced reflex 
cough. In a sub-group of 20 stroke patients with weak volitional cough (mean PCF 
220 L/min, SD 80), PCF of capsaicin-induced reflex cough was on average 184 
L/min (SD 130) higher than PCF of subjects’ maximal volitional cough effort. Cough 
flow traces indicate a pattern of cough augmentation during consecutive reflex cough 
bouts.  
It is suggested that the hypothesis may best be tested in a pragmatic applied clinical 
study, i.e. through the application of nebulized capsaicin in relevant clinical 
situations, as opposed to observational or experimental physiological studies.  
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BACKGROUND 
Nasotracheal suctioning (NTS) is a procedure for removing excess respiratory 
secretions (phlegm, mucus) from the tracheobronchial tree (1-3). NTS is indicated in 
patients who are unable to cough and clear excess respiratory secretions, and who 
are therefore at high risk of serious breathing difficulty due to impaired ventilation 
and gas exchange (1-5). Patients receiving NTS typically develop excess respiratory 
secretions acutely, for example due to pneumonia, and often against the background 
of acquired neuro-disability, a degenerative neurological condition, dementia, old 
age, chronic respiratory disease, decreased immune response, or general frailty. 
Inability to actively cough and clear in such a patient may be due to difficulty in 
initiating volitional coughs, for example in patients with cognitive impairments or 
reduced level of consciousness; insufficient effort of volitional cough;  respiratory 
muscle weakness; or poor neuro-muscular co-ordination of cough. The latter refers 
to co-ordination between respiratory muscle action and rapid glottis closure and 
opening, which is achieved by intrinsic laryngeal muscle action and is a defining 
feature of cough (6). Any of these problems may be compounded by high viscosity of 
secretions, bronchospasm, pain when breathing or coughing, and patient immobility.  
 
  
NTS is most commonly performed by physiotherapists and nurses, as a last-resort 
treatment when alternative, non-invasive and non-pharmacological modalities for 
secretion clearance have been unsuccessful (4,5). Examples for commonly applied 
non-invasive non-pharmacological treatments for secretion clearance are 
positioning, mobilisation, manually assisted cough, intermittent positive pressure 
breathing, and mechanical insufflation-exsufflation (2-5,7,8). For the purpose of this 
paper, NTS refers to the insertion of a flexible suction catheter (typically around 50 
cm in length and with a diameter of 2-6 mm, e.g. Pennine Healthcare, Derby, 
England) to the patient’s trachea. The suction catheter is inserted through either the 
nostril or the mouth, usually with the use of a nasopharyngeal or oropharyngeal 
(Guedel) airway, in a self-ventilating, non-intubated and non-tracheotomized patient 
(figure 1). NTS does not refer to suctioning of an intubated or tracheotomized 
patient, where the suction catheter is inserted through the endotracheal tube, 
tracheostomy tube, or a patent tracheostomy.  
 
INSERT FIGURE 1 ABOUT HERE 
 
In the United Kingdom, patients requiring NTS may receive hospital care under an 
agreed ‘ceiling of treatment’, which stipulates that the patient will receive active 
‘ward-based’ treatment (intravenous antibiotics and fluids, supplemental high flow 
oxygen, humidification and nebulisation, intensive respiratory physiotherapy); but will 
not receive intubation and ventilation (i.e. intensive care level of treatment). Under 
these circumstances, NTS is often an important treatment modality for preventing 
progressive respiratory deterioration and arrest during an acute episode of care. 
Another clinical scenario, in which NTS may be applied, is assisted airway clearance 
  
following removal of an endotracheal tube (extubation) or tracheostomy tube 
(decannulation). Secretion clearance in patients with impaired but recovering cough 
may for a period of time be assisted through NTS, potentially preventing the need for 
re-intubation or re-insertion of a tracheostomy tube, and thus supporting a successful 
respiratory wean. In some healthcare systems, NTS may also be delivered 
preventatively as part of a ‘bronchopulmonary hygiene’ protocol for patients who are 
at high risk of developing acute hypersecretion and secretion retention.  
 
NTS is regarded a core clinical skill within the scope of respiratory physiotherapy 
practice in the United Kingdom. But while NTS is a regularly performed and valuable 
procedure, it is also:  
(a) a highly unpleasant procedure for patients, because it is performed without 
sedation or local anaesthetic (2,3,9);  
(b) a blind invasive procedure, with risk of serious adverse events, such as 
hypoxaemia, bradycardia due to vagal stimulation, cardiac arrhythmia, 
bronchospasm, laryngospasm, introduction of pathogens to the lungs via the 
suction catheter, and trauma and bleeding from the mucosa or tracheal wall (1-3);  
(c) an advanced technical skill, requiring staff training and practice for competent 
execution and skill maintenance (1-3).  
 
These three aspects of NTS – negative patient experience, risk of adverse events, 
and technical skill required – provide the rationale for exploring a potential alternative 
that is non-invasive and carries much fewer risks; is convenient to adopt widely in 
clinical practice; and could achieve the same objective as NTS, but providing better 
patient experience.  
  
 
THE HYPOTHESIS 
It is hypothesized that instead of having to undergo NTS, a patient could clear 
retained lung secretions by inhaling nebulized capsaicin, which stimulates short-lived 
but vigorous bouts of reflex coughing. These bouts of reflex coughing could achieve 
movement of secretions from the lungs into the oropharynx, allowing the patient to 
spit out or have secretions cleared by suctioning from the oropharynx.  
 
The application of capsaicin-induced reflex cough for this purpose presents a novel 
and original hypothesis, developed by the author and based on his clinical 
experience in respiratory physiotherapy and research experience in clinical 
neuroscience.  
 
EVALUATION OF THE HYPOTHESIS 
The hypothesis presented here is based on the following stepwise rationale:  
(1) In health, respiratory secretions (phlegm, mucus) are cleared continuously from 
the lower airways into the oropharynx, mainly through the mucociliary escalator 
mechanism, supplemented by occasional clearing of the throat and infrequent 
coughs (8,10).  
(2) If there is hypersecretion, cough becomes an increasingly important additional 
mechanism for clearing secretions from the lower airways (8,10).  
(3) The mechanism by which cough achieves movement of respiratory secretions 
from the lungs into the oropharynx is high expiratory airflow during the expulsive 
  
phase of cough. The resulting sheer forces achieve movement of secretions 
along the bronchi and trachea (8,10-12).  
(4) Patients who require NTS are unable to effect sufficiently high expiratory cough 
flow in either volitional or spontaneous cough. But it is a common clinical 
observation that during NTS, patients will often exhibit reflex coughs in response 
to mechanical stimulation of the tracheal wall or carina by the suction catheter tip. 
These reflex coughs triggered during NTS often shift secretions from the 
bronchial tree towards the trachea, where they are suctioned; or achieve 
clearance of secretions from the lower airways into the oropharynx.  
(5) It is hypothesized that instead of having to undergo NTS, a patient could inhale 
nebulized capsaicin. Vigorous capsaicin-induced reflex coughs could achieve 
movement of secretions from the lungs into the oropharynx, allowing the patient 
to spit out or have secretions cleared by suctioning from the oropharynx, thus 
avoiding the need for suction catheter penetration to the trachea.  
 
Application of capsaicin in medical research and practice 
Capsaicin is a component extracted from cayenne pepper, with the molecular 
formula C18H27NO3 (13,14). Above a certain threshold, inhaled nebulized capsaicin 
will trigger reflex coughs in humans by acting on chemoreceptors in the lower 
airways (15-18). Since the 1980s, this property of capsaicin has been utilized for 
cough sensitivity testing in respiratory research (17). In cough sensitivity testing, 
nebulized irritants (most commonly citric acid, tartaric acid and capsaicin) are 
administered in increasing concentration and inhaled by the subject, until a reflex 
cough response is elicited (17). In this context, capsaicin has been administered to 
multitudes of healthy individuals and patients of different age groups over the years, 
  
including patients with asthma, chronic obstructive pulmonary disease, 
bronchiectasis, stroke and Parkinson’s disease, with a documented high level of 
patient safety and no serious adverse events (15-25). The use of capsaicin for cough 
sensitivity testing is currently its only application in respiratory medicine and 
research. In a different application, capsaicin is utilized in topical analgesics for its 
neurotoxic and desensitizing properties (14).  
 
Evidence in support of the hypothesis 
Some data in support of the hypothesis are available from the author’s previous 
research, in which 82 individuals with acute stroke underwent assessments of peak 
cough flow (PCF), an indicator of cough effectiveness (25,26).  
 
Higher peak cough flow in reflex cough than volitional cough 
PCF was assessed for both maximal volitional cough effort and capsaicin-induced 
reflex cough (25,26). A sub-group of 20 patients with weak volitional cough (mean 
PCF 220 L/min, SD 80) showed higher PCF during capsaicin-induced reflex cough 
than in maximal volitional cough (table 1). PCF of capsaicin-induced reflex cough 
was on average 184 L/min (SD 130) higher than PCF of subjects’ maximal volitional 
cough effort. This suggests that capsaicin-induced reflex cough under such 
circumstances could be more effective in shifting excess respiratory secretions from 
the lungs into the oropharynx than volitional cough. These observed magnitudes of 
PCF of volitional and reflex cough also largely align with values of PCF that are 
thought to indicate the threshold for successful secretion clearance and which, 
depending on patient group and clinical scenario, range from 160 to 270 L/min 
(4,8,27,28)  
  
 
INSERT TABLE 1 ABOUT HERE 
 
The data shown in table 1 are from patient assessments, in which nebulized 
capsaicin was delivered in up to 12 rounds, starting at a concentration of 0.49 µMol/L 
and doubling in dose up to a maximum of 1,000 µMol/L. These are the same 
escalating concentrations used in the recommended standardized protocol for cough 
sensitivity testing (17). But while in cough sensitivity testing the aerosol is delivered 
during a single inspiration and timed to 1.2 seconds to ensure consistent dosage, 
stroke patients in the above study inhaled capsaicin for up to 60 seconds at each 
concentration. This is a relevant consideration for the proposed hypothesis. Midgren 
et al. observed in their study of capsaicin-induced cough in healthy humans (15) that 
subjects were able to continue breathing through 60 seconds of inhaling nebulized 
capsaicin, which was not possible with citric acid. Capsaicin therefore appears to 
lend itself to prolonged inhalation, which is an advantage for the application 
proposed here.  
 
Cough augmentation through consecutive reflex cough bouts 
It is suggested that the patient will inhale nebulized capsaicin at increasing 
concentrations through a facemask for 60 seconds at a time. When the threshold is 
reached, at which vigorous reflex coughs are elicited, it is envisaged that this will 
result in the cough pattern observed in the above study: a number of reflex coughs in 
rapid succession (observable in the cough flow-time trace as ‘cascades’ of reflex 
cough spikes) was followed by a deep inspiration, which in turn delivered more 
aerosol to the receptor sites and triggered a further reflex cough bout, and so on 
  
(figure 2). The physiological significance of this cough flow pattern is that during the 
first ‘cascade’ of reflex coughs the patient is likely to expel from their expiratory 
reserve volume, which increases the potential for the following inspiration to exceed 
the resting tidal volume, i.e. generate a greater pre-cough inspiratory volume for the 
following cough bout. Techniques for increasing pre-cough inspiratory volume are an 
important aspect of cough augmentation treatments (2,3,5,7,8), because greater 
inspiratory volume maximizes the potential for higher expiratory cough flow (29) and 
therefore effective secretion clearance. In addition, greater inspiratory volume bio-
mechanically optimises the length-tension relationship of expiratory muscles and 
allows for higher intrathoracic pressure during the compression phase of cough (30). 
Figure 2 illustrates this effect in the cough flow trace of a stroke survivor with very 
weak volitional cough. In this example, the PCF of repeated maximal volitional cough 
efforts averaged 204 L/min, with a maximum of 276 L/min. In contrast, the PCF of 
repeated capsaicin-induced reflex coughs averaged 291 L/min, culminating in one 
particularly strong cough at 494 L/min PCF in the last of 4 cough bouts.  
 
INSERT FIGURE 2 ABOUT HERE 
 
Evidence against the hypothesis 
As a potential limitation of the hypothesis, it may be considered that the proposed 
intervention is dependent on the integrity of the patient’s cough reflex. Patients with 
diseases and conditions that impede the neurophysiology of reflex cough may 
therefore not show the hypothesized response of secretion clearance through 
capsaicin-induced reflex cough.  
 
  
The main reflexogenic zones for cough are located in the larynx and the 
tracheobronchial tree, where capsaicin stimulates primarily unmyelinated C-fibres 
(6,16,31-33). Sensory afferents are conveyed via the superior laryngeal nerve and 
vagal afferents from the lower airways, and terminate in the tractus solitarii in the 
brainstem. From there, second-order neurons project extensively to the pontine and 
medullary respiratory centres. The efferent pathways of reflex cough lead via upper 
motor neurons to the spinal motor neurons supplying the inspiratory and expiratory 
muscles (effecting inspiratory and expiratory muscle action); via cranial motor 
neurons to the intrinsic laryngeal muscles (effecting co-ordinated glottis closing and 
opening); and via sympathetic and parasympathetic efferents to the smooth airway 
muscles (effecting bronchoconstriction) (18, 33,34).  
 
Conditions causing structural and/or functional impairment of the cough reflex 
Theoretically, any structural and/or functional impairment at any point of the cough 
reflex arc could lead to failure of the proposed intervention. For example, should 
there be decreased chemosensitivity to capsaicin or denervation of the sensory 
afferents, this could lead to an inability to elicit vigorous reflex cough bouts, even at 
the highest available concentration of capsaicin. Similarly, in conditions causing 
irreversible denervation and atrophy of respiratory muscles (e.g. motor neuron 
disease or cervical/thoracic spinal cord injury), it could be assumed that reflex cough 
is unlikely to be more effective for clearing secretions than volitional cough, as the 
(in)ability of the respiratory muscles to generate the necessary intrathoracic 
pressures would probably remain the same for both volitional and reflex cough. 
However, it may not be appropriate to reason deductively in this case, because 
current neurophysiological knowledge about reflex cough in humans derives mainly 
  
from animal models, and experimental evidence from human populations is rather 
limited (6,8,16,18).  
 
Few studies have investigated reflex cough in those patient groups and under those 
circumstances that are relevant to the hypothesis presented here, for example in 
conditions that could be expected to disrupt cough sensory afferents (6). Smith and 
Wiles conducted a study in the 1990s (35), in which reflex cough sensitivity to 
capsaicin was assessed in 28 patients with different neurological diagnoses, 
including multiple sclerosis, encephalitis, motor neuron disorders, myopathy and 
myasthenia. Capsaicin was delivered in incremental concentrations from 7 to 2,000 
µMol/L, and this was sufficient to elicit reflex coughs in all participants at an average 
concentration of 50.6 µMol/L. A comparison of cough sensitivity thresholds between 
those patients who, based on their diagnosis, were expected to have impaired 
pharyngeal or laryngeal sensory function and those that did not, did not show any 
difference in capsaicin responses. A more recent small study of 4 adults with 
traumatic brain injury showed that nebulized capsaicin at 200 µMol/L triggered reflex 
cough in all participants; although urge to cough and number of cough events were 
reduced in comparison with healthy norm reference values (36). The authors offer a 
discussion of the potential contributing factors, such as dampening of sensory inputs, 
central processing of these inputs, disrupted motor pathways, and/or peripheral 
muscle weakness and atrophy, including the possibility that surgical tracheostomy 
may have affected stimulus-induced cough in these individuals. In a similar vein, it 
has generally been assumed that lung transplantation leads to complete sensory and 
autonomic denervation of the airways, including loss of cough reflex. But recent 
  
observations indicate that with time there is the possibility of functional and structural 
restoration of reflex cough after lung transplantation (37).  
 
Lower peak cough flow in reflex cough than volitional cough 
With respect to PCF and effectiveness of reflex cough, Brandimore et al. (24) and 
Wheeler Hegland et al. (23) have investigated differences in respiratory kinematics 
and airflow between volitional cough and capsaicin-induced reflex cough. The 
authors examined various parameters in 25 healthy volunteers (24) and 20 patients 
with idiopathic Parkinson’s disease (23). One finding, which is in conflict with, and 
therefore pertinent to the hypothesis presented here, is that in both groups of 
participants PCF of capsaicin-induced reflex cough was lower than PCF of volitional 
cough; and that in both studies about one fifth of participants did not respond to 
capsaicin. These findings may be explained by the fact that in these studies 
capsaicin was administered in one single dose (i.e. for one breath) and up to a 
maximum concentration of 200 µMol/L. Brandimore et al. emphasise that the method 
of elicitation of cough, whether reflex or volitional, results not only in 
neurophysiological differences, but also in kinematic and airflow differences (24). For 
the purpose of this hypothesis, it is therefore suggested that the contrary data 
presented above in support of the hypothesis can be explained by the difference in 
the administration of nebulized capsaicin (i.e. delivery of up to 1,000 µMol/L of 
capsaicin for up to 60 seconds at a time).  
 
Attenuation of the cough reflex due to reduced level of consciousness 
Lastly, some studies have examined reflex cough in patients with reduced level of 
consciousness. In their short report from 1994, Moulton and Pennycook (38) 
  
describe a sample of 76 patients admitted at the emergency department, who 
presented in a comatose state (Glasgow Coma Scale scores from 3 to 8) due to drug 
overdose, alcohol intoxication, head injury, post-ictal state, etc. The presence of 
cough reflex was assessed during airway management procedures such as 
suctioning, i.e. using a mechanosensory stimulus, and described as normal, 
attenuated or absent. While there were more observations of absent cough reflex in 
patients with lower levels of consciousness on the Glasgow Coma Scale, there were 
also patients in which cough reflex was present at the lowest level of consciousness 
(37). More recently, this study has been replicated in a larger sample of 208 patients 
admitted with trauma, poisoning, neurological and cardiorespiratory conditions, etc., 
and level of consciousness ranging from full (Glasgow Coma Scale score 15) to 
comatose (Glasgow Coma Scale score ≤8) (39). A higher proportion of attenuated 
and absent reflex cough was observed in patients with reduced level of 
consciousness; although about a quarter of comatose patients did exhibit a normal 
cough reflex. In the context of the hypothesis presented here, these findings are 
relevant in that they demonstrate that reflex cough is preserved in a proportion of 
individuals with reduced level of consciousness. However, in these studies cough 
was elicited by mechanosensory stimulation, and it may not be assumed that 
chemosensory stimulation with capsaicin would achieve the same outcome.  
 
Testing the hypothesis 
Literature searching 
A thorough literature search was conducted in June 2016, and updated on an 
ongoing basis, using auto-alerts and manual re-runs. Electronic databases of 
indexed peer reviewed scientific journals (PubMed, CINAHL Plus, Embase, AMED, 
  
MAG Online Library, Web of Science, etc.), grey literature (NICE Evidence Search, 
OpenGrey), and registries of completed and ongoing clinical studies (NIHR 
Evaluation Trials and Studies portfolio, HRA/RES database of research summaries, 
ISCRTN registry, EU Clinical Trials Register, and ClinicalTrials.gov) were searched 
using relevant search terms. Of note, the search strategy also included the two 
commonly used alternative cough stimulants to capsaicin, citric and tartaric acid. Out 
of 3,792 results, 21 were reviewed in full-text, including recent systematic and 
narrative reviews of interventions for respiratory secretion management (7-9,28), and 
no evidence addressing the hypothesis was identified.  
 
An applied and pragmatic experimental approach 
The studies described above illustrate that there is limited experimental evidence 
available to answer the hypothesis deductively and based on existing neuro- and 
pathophysiological knowledge. Furthermore, the hypothesis applies to a scenario 
that clinicians approach with primarily problem-based clinical reasoning (i.e. 
addressing the problem of secretion retention and impaired airway clearance, 
against the background of the individual patient’s medical diagnosis), as opposed to 
primarily diagnosis-based reasoning (i.e. focusing on the management of one 
particular medical diagnosis, against the background of its possible sequelae and 
problems). The hypothesis presented here is relevant to a variety of patient groups, 
and therefore it may be suggested that it should be understood as an applied clinical 
hypothesis (i.e. conceived and developed from observations in clinical practice and 
research), as opposed to a hypothesis that has been deduced primarily from 
(patho)physiological knowledge of one particular disease or condition. It follows that 
this should be reflected in the method of testing the hypothesis. It is therefore 
  
suggested that an applied and pragmatic experimental approach (i.e. trialling the 
proposed intervention in ‘real life’ clinical situations) is preferable over observational 
or experimental physiological studies, which may expand the theoretical knowledge 
base but are unlikely to yield data to verify or reject the hypothesis outright.    
 
A Clinical Trial of an Investigational Medicinal Product (CTIMP) 
The design of such an applied and pragmatic research approach could be modelled 
on the phases for development of new pharmaceutical products (40). From a 
regulatory standpoint, although the safety of nebulized capsaicin for the purpose of 
cough sensitivity testing in research has been well documented in the literature 
(20,21), the use of nebulized capsaicin in the application proposed here implies its 
use for curative purposes, and would therefore require development of the 
formulation according to procedures and regulatory standards for developing 
Investigational Medicinal Products (IMPs). To test the proposed application in the 
first instance, and corresponding to phase I of a Clinical Trial of an Investigational 
Medicinal Product (CTIMP), capsaicin-induced reflex cough could be trialled in a 
small number of patients, for example in a case series or cohort study design, with 
the main objective of establishing its safety and feasibility in this particular clinical 
context. Once safety and feasibility have been established, efficacy of the proposed 
intervention may then be investigated in a phase II pragmatic randomized controlled 
trial, leading on to a phase III trial to compare safety and effectiveness of the novel 
intervention against existing treatment modalities.  
 
  
CONSEQUENCES OF THE HYPOTHESIS AND DISCUSSION 
The hypothesis described here concerns NTS, a procedure that, although an 
important treatment modality in chest physiotherapy and respiratory care, presents a 
somewhat hidden area of clinical practice. This may account for the dearth of 
scientific publications and lack of research and development around NTS in the past.  
 
Improved patient experience, commercial exploitation and health economic benefit 
The proposed alternative to NTS has the potential to provide a convenient and safe 
non-invasive treatment modality for acute secretion retention and improve patient 
experience. As described above, this respiratory problem is not linked to any 
particular medical diagnosis. The intervention could therefore benefit neurologic, 
respiratory, geriatric, general medical and surgical patients, for example individuals 
with dysphagia and aspiration pneumonia, or patients who are deconditioned 
following a prolonged respiratory wean. This hypothesis also indicates the potential 
to re-purpose a known pharmaceutical substance (capsaicin) in a novel application, 
from which a number of possible consequences for health-economic impact may be 
considered. The potential for commercial exploitation, for example in developing a 
user-friendly capsaicin nebulizer ‘kit’, is obvious. In addition, the proposed 
intervention may provide a treatment option suitable for community settings. Due to 
safety considerations, NTS is rarely performed outside of hospital settings, but 
nebulized capsaicin could be applied, for example, in the community management of 
patients with recurrent episodes of hypersecretion and risk of acute secretion 
retention. This could deliver whole system savings through reduction of hospital bed 
days, in addition to improving patient comfort and convenience through offering an 
option for community management. Another possible consequence could be 
  
efficiencies in staff resources. As the clinical skill of administering nebulized 
capsaicin can be acquired and maintained more easily than NTS, savings could be 
realized through more efficient staff training and more widespread skill competency 
amongst members of physiotherapy or nursing staff, which could relieve more 
experienced and senior members of staff within a local health economy.  
 
 
Conclusion 
In conclusion, it is hypothesized that capsaicin-induced reflex cough could be used 
instead of NTS as a treatment for acute secretion retention in self-ventilating, non-
intubated and non-tracheotomized patients. Some clinical data from a stroke trial are 
available to support the hypothesis, while some neuro- and pathophysiological 
considerations indicate potential limitations of the hypothesis. Because the 
hypothesis was conceived and developed based on observations from clinical 
practice and applied clinical research, it is suggested that a pragmatic and applied 
clinical research design is best suited to test the hypothesis.  
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Figure 1. Placement of nasotracheal catheter for suctioning the tracheobronchial 
tree. Reproduced by the kind permission of Wolters Kluwer Health from Nettina SM. 
Lippincott Manual of Nursing Practice. 9th ed. London: Lippincott Williams & Wilkins. 
2010. p. 233.  
 
 
Figure 2. Cough pattern (flow-time trace) of a patient with stroke; (a) maximal 
volitional cough efforts showing 7 distinct cough spikes with mean (range) peak 
cough flow (PCF) of 204 L/min (113, 276); (b) capsaicin-induced reflex cough bouts 
showing 11 distinct cough spikes in 4 ‘cascades’ with mean (range) PCF of 291 
L/min (203, 494).  
 
 
 
 
 
 
 
  
Table 1. Comparison of peak cough flow of maximal volitional cough effort and 
capsaicin-induced reflex cough in 20 acute stroke patients. Data are from a 
subgroup of patients in a previous stroke trial (Kulnik et al, 2015).  
Participant 
number* 
Peak cough flow of 
maximal volitional 
cough effort (L/min) 
Peak cough flow of 
capsaicin-induced 
reflex cough (L/min) 
Difference (L/min) 
01 129 414 285 
06 254 347 93 
07 271 329 58 
15 319 500 181 
20 170 400 230 
22 176 512 336 
24 395 559 164 
25 255 306 51 
26 77 579 502 
27 237 504 267 
34 269 410 141 
42 167 194 27 
43 333 371 38 
46 131 433 302 
49 200 336 136 
51 232 419 187 
58 285 319 34 
67 184 557 373 
71 116 314 198 
76 206 276 70 
* Participant number derived from original trial participant code 
